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TO THE EDITOR
The second messenger cAMP upregu-
lates gene expression of microphthal-
mia-associated transcription factor
(MITF) or tyrosinase in skin pigmenta-
tion (Busca and Ballotti, 2000).
a-Melanocyte-stimulating hormone
(a-MSH) and forskolin are cAMP
elevators and stimulate melanin
production in melanocytes (Busca and
Ballotti, 2000). Intracellular cAMP
activates protein kinase A (PKA) from
an inactive holoenzyme complex consi-
sting of a regulatory subunit dimer
bound to two catalytic subunits (Kim
et al., 2007). The regulatory subunit of
PKA cooperatively binds with two
cAMP molecules, concomitantly relea-
sing the catalytic subunit and thereby
allowing phosphorylation of PKA sub-
strates including the Ser-133 residue of
cAMP-responsive element-binding pro-
tein (CREB; Taylor et al., 2008). The
level of phospho (p)-CREB protein can
be used as an active index in the up-
regulation of MITF, a basic helix-loop-
helix transcription factor crucial for
melanocyte pigmentation (Vachtenheim
and Borovansky, 2010). In turn, MITF
binds to the M box or E box in
the promoter region of the tyrosinase
gene for transcriptional activation
(Vachtenheim and Borovansky, 2010).
Abnormal accumulation of melanin
pigments is responsible for pigmented
disorders such as melasma, freckles,
and senile lentigo, which can be sub-
stantially ameliorated by treatment with
arbutin or other tyrosinase inhibitors
(Maeda and Fukuda, 1996; Ortonne
and Passeron, 2005). Cinnamaldehyde
displays an anti-aging potential in skin
treatment and inhibits tyrosinase activity
in mushrooms (Lee, 2002; Takasao
et al., 2012), but its effect on mela-
nocyte pigmentation remains to be
defined. Here, 4-hydroxy-3-methoxy-
cinnamaldehyde (4H3MC, Supplemen-
tary Figure S1a online) inhibited
a-MSH-induced melanin production in
B16 mouse melanoma cells and pri-
mary human melanocytes with more
effectiveness than cinnamaldehyde,
4-hydroxy-3-methoxycinnamic acid,
4-hydroxycinnamic acid, and cinnamic
acid (Figure 1a and b, Supplementary
Figure S1b online). Moreover, 4H3MC
inhibited melanin production in B16
cells stimulated with other cAMP
elevators, such as N6,20-O-dibutyryl
(db)-cAMP and forskolin, in which
Rp-adenosine 30,50-cyclic monopho-
sphorothioate (Rp-cAMPS) and H-89
were also effective (Supplementary
Figure S2a and b online). Rp-cAMPS is
a cell-permeable cAMP antagonist that
interrupts PKA activation, and H-89 is a
PKA inhibitor that targets catalytic activ-
ity after dissociation and activation from
the holoenzyme complex (Wu et al.,
2004; Lochner and Moolman, 2006).
However, 4H3MC at the concentra-
tions with antimelanogenic activity did
not affect the viability of B16 cells
(Supplementary Figure S2c online),
excluding nonspecific cytotoxicity. To
understand the in vivo efficacy of
4H3MC, we carried out UVR–induced
skin pigmentation in guinea pigs
(Supplementary Figure S3a online).
Topical treatment with 4H3MC
decreased melanin contents in the basal
layer of the epidermis and ameliorated
visual skin pigmentation in UV-
irradiated dorsal skins of guinea pigs
(Figure 1c, Supplementary Figure S3b
online).
Treatment with 4H3MC itself did not
affect cAMP levels in a-MSH-activated
B16 cells (Supplementary Figure S4a
online). To elucidate an antimelano-
genic mechanism of 4H3MC, we tested
whether it could affect cAMP-induced
proximal signaling events. Treatment
with 4H3MC or Rp-cAMPS inhibited
the dissociation of catalytic subunit-a
(PKA-Ca) from the regulatory subunit IIb
of PKA (PKA-RIIb) in cAMP-elevated
B16 cells or primary human melano-
cytes, whereas H-89 was not effective
(Figure 2a and b, Supplementary Figure
S4b online). Moreover, 4H3MC inhib-
ited a-MSH-induced PKA activation in
B16 cells but did not affect in vitro
kinase activity of cell-free PKA with
catalytic subunit only (Supplementary
Figure S5a and b online). These results
indicate that 4H3MC directly inter-
rupted cAMP-induced dissociation and
activation of PKA holoenzyme.
We next performed a fluorescence
analysis with 8-[j-575]-cAMP, specifi-
cally probing the cAMP-binding A and
B sites on the regulatory subunit of PKA
(Moll et al., 2008). 8-[j-575]-cAMP
increased fluorescence values upon bin-
ding to PKA-RIIb polypeptide in cell-free
reactions (Figure 2c). Treatment with
non-fluorescent 4H3MC dose depen-
dently decreased the fluorescence inten-
sity of 8-[j-575]-cAMP (Figure 2c),
indicating the displacement of 8-[j-
575]-cAMP from the complex with
PKA-RIIb polypeptide. This mechanism
of action was reversible, as fluore-
scence intensity was recovered in the
pre-treatment with 4H3MC followed by
competitive titration with excess 8-[j-
575]-cAMP (Supplementary Figure S6
online). Consistent with this, 4H3MC
was well fitted into the cAMP-binding
A or B site on the crystal structure ofAccepted article preview online 7 August 2013; published online 12 September 2013
Abbreviations: CREB, cAMP-responsive element-binding protein; db-cAMP, N6,20-O-dibutyryl-cAMP;
4H3MC, 4-hydroxy-3-methoxycinnamaldehyde; MITF, microphthalmia-associated transcription factor;
a-MSH, a-melanocyte-stimulating hormone; PKA, protein kinase A; PKA-RIIb, regulatory subunit IIb of
PKA; Rp-cAMPS, Rp-adenosine 30,50-cyclic monophosphorothioate
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PKA-RIIb under the most energetically
favorable simulation (Supplementary
Figure S7a and b online). Thereby,
4H3MC mimicked Rp-cAMPS or bisa-
bolangelone in the antimelanogenic
mechanism, even though its skeleton
structure is not analogous to those
of the agonist cAMP and the antagonist
Rp-cAMPS or bisabolangelone (Roh
et al., 2013).
4H3MC consequently suppressed
downstream melanogenic pathways.
Treatment with 4H3MC inhibited PKA-
catalyzed CREB phosphorylation in
a-MSH- or db-cAMP-activated melano-
cyte cultures, whereas no significant
change was observed in total levels of
CREB (Figure 2d, Supplementary Figure
S8a and b online). In this experiment,
anti-p-CREB antibody also recognized
the phosphorylated form of activa-
ting transcription factor-1, closely relat-
ing to p-CREB in structure and function
(Hummler et al., 1994). Moreover,
topical treatment with 4H3MC dimi-
nished CREB phosphorylation in UV-
irradiated dorsal skins of guinea pigs
(Figure 2e). CREB-responsive CRE motifs
appear to be essential for maximal MITF
induction in cAMP-elevated melano-
cytes, and MITF has an important role
in the melanocyte-specific expression
of tyrosinase gene, even though the pro-
moter of MITF or tyrosinase gene contains
several cis-acting elements (Vachtenheim
and Borovansky, 2010). Treatment with
4H3MC suppressed a-MSH-induced gene
expression of MITF or tyrosinase in B16
cells at the transcription level, as did
Rp-cAMPS (Supplementary Figures S9a–c
and S10a–c online). Moreover, topical
treatment with 4H3MC attenuated the
protein or mRNA levels of both MITF
and tyrosinase in UV-irradiated dorsal
skins of guinea pigs (Supplementary
Figure S11a and b online).
In conclusion, the cAMP-binding site
of PKA is a molecular target of 4H3MC
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Figure 1. 4-Hydroxy-3-methoxycinnamaldehyde (4H3MC) inhibits melanin production in a-melanocyte-stimulating hormone (a-MSH)-activated melanocyte
cultures and UV-irradiated dorsal skins of guinea pigs. B16 cells were stimulated with a-MSH in the presence of 4H3MC or arbutin for 3 days (a) and primary
human melanocytes for 8 days (b). Melanin contents were measured with synthetic melanin as a standard and then normalized to cell numbers. Data are
represented as mean±SD from three separate experiments. #Po0.05 vs. media alone–added group. *Po0.05 vs. a-MSH alone-stimulated group. (c) Dorsal skins
of guinea pigs were topically treated with 4H3MC followed by UVR. Skin tissues biopsied at the 4th week after starting UVR were sectioned and then stained with
Fontana–Masson stain (silver nitrate). Bar¼ 100mm.
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Figure 2. 4-Hydroxy-3-methoxycinnamaldehyde (4H3MC) inhibits a-melanocyte-stimulating hormone (a-MSH)- or UV-induced dissociation and activation of
protein kinase A (PKA) holoenzyme. B16 cells (a) or primary human melanocytes (b) were pre-treated with 4H3MC for 2 hours and stimulated with a-MSH for
10–20 minutes in the presence of 4H3MC. Whole cell extracts were subjected to immunoprecipitation (IP) with antibody against regulatory subunit IIb of
PKA (PKA-RIIb), followed by western blot analysis (WB) with antibody against PKA-Ca or PKA-RIIb to detect the co-precipitation. (c) Fluorescence probe
8-[j-575]-cAMP (5mM) was incubated with cell-free PKA-RIIb polypeptide (2mg ml 1) for 2 hours to reach stable fluorescence values and then treated with
4H3MC for 2 hours. Relative fluorescence units (RFU) were measured under emission at 590–670 nm and excitation at 575 nm. (d) Primary human melanocytes
were pre-treated with 4H3MC for 2 hours and stimulated with a-MSH for 30–40 minutes in the presence of 4H3MC. Cell extracts were subjected to WB with
anti-p-CREB or anti-CREB antibody. (e) Dorsal skins of guinea pigs were topically treated with 4H3MC followed by UVR. Skin tissues were biopsied at the
4th week after starting UVR. Protein extracts from skin specimens were subjected to WB with anti-p-CREB or anti-CREB antibody.
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in the antimelanogenic action down-
regulating the expression of MITF or
tyrosinase gene in cAMP-elevated mela-
nocyte cultures and UV-irradiated dor-
sal skins of guinea pigs (Supplementary
Figure S12 online). Finally, this study
suggests a potential application of
4H3MC in the treatment of hyperpig-
mented skin disorders.
Animal experiments were carried out
according to the protocols approved by
Animal Experimentation Ethics Commit-
tee in CBNU institute.
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TO THE EDITOR
Among the several characteristics of
malignant melanoma, insensitivity to
anti-cancer agents is a frequent clinical
problem in the treatment of patients
(Grossman and Altieri, 2001). In fact,
the most commonly used chemotherapy
agents cisplatin and dacarbazine for
malignant melanoma elicit a response
rate of only 10% (Flaherty, 2010).
The small-molecule inhibitor of
BRAF, vemurafenib (also known as
PLX4032), elicits potent tumor regres-
sion in patients with BRAF-positive stage
IV melanoma (Huang et al., 2012), and
its use is expected in patients harboring
the BRAFV600E mutation (Tsai et al.,
2008). However, vemurafenib is not
effective against melanomas with wild-
type BRAF protein (Joseph et al., 2010).
Acral lentiginous melanoma (ALM) is
one of the subtypes of cutaneous mela-
noma most frequent in colored races
(Bradford et al., 2009). In fact, only
about 10% of ALM cases harbor the
BRAFV600E mutation, compared with
over 60% of cases of superficial spread-
ing melanoma (SSM), which is most fre-
quent in Caucasian populations (Saldanha
et al., 2006). Because these melanomas
are insensitive to BRAF inhibitors (Joseph
et al., 2010), a search for molecular
targets that would enhance sensitivity to
standard treatment with cisplatin or
dacarbazine would seem justified.
To address the genes responsible for
drug resistance in melanoma, whole-
exome sequencing was performed. We
identified a single-nucleotide deletion in
codon 507 from exon 4 of the KEAP1
gene, common to MM-RU and PM-WK,
as a candidate gene for drug resistanceAccepted article preview online 12 August 2013; published online 19 September 2013
Abbreviations: ALM, acral lentiginous melanoma; CDDP, cis-diamminedichloro-platinum (II); DTIC, 5-(3,
3-dimethyl-1-triazenyl) imidazole-4-carboxamide; FSM, frameshift mutant; ROS, reactive oxygen species;
SSM, superficial spreading melanoma
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